Zhejiang Hisun Pharmaceutical Co., Ltd.

Zhaozhao Zhang

Liang Zhang

Zhiqing Yang

Jian Chai

Xiangyang Zhang

Hairong Luo

Jinyi Xu

Chuan Liu

Zhi Chen

The present invention relates to novel crystal forms M and N of dabigatran etexilate mesylate and preparation method and uses thereof, wherein the X-Ray powder diffractogram of the crystal form M has characteristic peaks at the following 2&#x3b8; diffraction angles: 5.7&#xb1;0.2&#xb0;, 6.2&#xb1;0.2&#xb0;, 11.2&#xb1;0.2&#xb0;, 12.4&#xb1;0.2&#xb0;, 18.2&#xb1;0.2&#xb0;, 21.4&#xb1;0.2&#xb0;, 21.8&#xb1;0.2&#xb0; and 23.6&#xb1;0.2&#xb0;; and the X-Ray powder diffractogram of the crystal form N has characteristic peaks at the following 2&#x3b8; diffraction angles: 6.0&#xb1;0.2&#xb0;, 11.8&#xb1;0.2&#xb0;, 18.2&#xb1;0.2&#xb0;, 21.6&#xb1;0.2&#xb0;, 24.4&#xb1;0.2&#xb0;, 27.7&#xb1;0.2&#xb0; and 29.7&#xb1;0.2&#xb0;. The crystal forms of the present invention have excellent properties in the aspects of leaching time, biological release, chemical stability and processing adaptability.

Crystal form of dabigatran etexilate mesylate and preparation method and use thereof

Growing community of inventors

Taizhou, China

Zhaozhao Zhang